OTCMKTS:ADOCY - ADOCIA/S Stock Price, News, & Analysis

Adocia SA, a clinical-stage biotechnology company, researches and develops formulations of pre-approved therapeutic proteins and peptides for the treatment of diabetes and other metabolic diseases. Its proprietary BioChaperone technological platform is designed and developed based on novel polymers, oligomers, and small molecules to enhance the effectiveness and/or safety of therapeutic proteins. The company's clinical product pipeline includes insulin formulations, such as BioChaperone Lispro U100 and U200, which are ultra-rapid formulations of insulin analogs; HinsBet U100, a rapid-acting formulation of human insulin; BioChaperone Combo, a combination of basal insulin glargine and rapid-acting insulin lispro; BioChaperone Pramlintide Insulin, a prandial combination of human insulin with amylin pramlintide; and BioChaperone Human Glucagon, an aqueous formulation of human glucagon. It is also developing BioChaperone Glargine Dulaglutide and BioChaperone Glargine Liraglutide that are combinations of insulin glargine with GLP-1s; BioChaperone Teduglutide, an aqueous formulation of teduglutide, a GLP-2 analog for the treatment of short bowel syndrome; and BioChaperone Glucagon GLP-1, a combination of glucagon and a GLP-1 receptor agonist for the treatment of obesity. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. Adocia SA was founded in 2005 and is headquartered in Lyon, France.

ADOCIA/S (OTCMKTS:ADOCY) Frequently Asked Questions

What is ADOCIA/S's stock symbol?

ADOCIA/S trades on the OTCMKTS under the ticker symbol "ADOCY."

Has ADOCIA/S been receiving favorable news coverage?

News stories about ADOCY stock have trended somewhat positive on Friday, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. ADOCIA/S earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the near term.

Who are some of ADOCIA/S's key competitors?

Some companies that are related to ADOCIA/S include Imperial Tobacco Group (IMBBY), LONZA GRP AG/ADR (LZAGY), H. Lundbeck A/S- (HLUYY), INDIVIOR PLC/S (INVVY), Turning Point Brands (TPB), Pharming Group (PHGUF), Standard Diversified Inc Class A (NYSEAMERICAN) (SDI), Gilla (GLLA), Healthier Choices Management (HCMC) and Special Diversified Opportunities (SDOIA).

Who are ADOCIA/S's key executives?

ADOCIA/S's management team includes the folowing people:

• Dr. Gérard Soula, Co-Founder, Chairman, CEO & Pres (Age 73)
• Mr. Olivier Soula, Co-Founder, Deputy CEO, Vice-Pres, Director of R&D and Director (Age 48)
• Mr. Rémi Soula, Co-Founder, Director of Bus. Devel. & Intellectual Property and Scientific Advisor
• Ms. Valerie Danaguezian, Chief Financial Officer and Admin. & Financial Director
• Ms. Geraldine Favre Soula, HR Devel. Director

How do I buy shares of ADOCIA/S?

Shares of ADOCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ADOCIA/S's stock price today?

One share of ADOCY stock can currently be purchased for approximately $19.70.

How big of a company is ADOCIA/S?

ADOCIA/S has a market capitalization of $136.32 million and generates $21.99 million in revenue each year.

What is ADOCIA/S's official website?

The official website for ADOCIA/S is http://www.adocia.com.

How can I contact ADOCIA/S?

ADOCIA/S's mailing address is 115 avenue Lacassagne, Lyon I0, 69003. The company can be reached via phone at 33-04-72-61-06-10 or via email at [email protected]